Status: Recruiting
Neoadjuvant Immunochemotherapy for LAOSCC
To evaluate the prognostic efficacy of neoadjuvant immunochemotherapy with tislelizumab, albumin paclitaxel and cisplatin followed by radical surgery and adjuvant therapy compared with standard therapy for patients with locally advanced and resectable oral squamous cell carcinoma.
Participants needed: 134
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Lai-ping ZhongUpdated: Mar 13, 2025Locations: 1
Eligibility criteria
Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0-1 [+8]
Unresolved grade 2 [(Common Terminology Criteria for Adverse Events (CTCAE 5.0)]... [+12]